Aug 2 (Reuters) - Zynerba Pharmaceuticals Inc ::ZYNERBA PHARMACEUTICALS REPORTS SECOND QUARTER 2018 FINANCIAL RESULTS AND OPERATIONAL HIGHLIGHTS.Q2 LOSS PER SHARE $0.89.Q2 EARNINGS PER SHARE VIEW $-0.78 -- THOMSON REUTERS I/B/E/S.TOPLINE RESULTS EXPECTED IN SECOND HALF OF 2019 FOR CONNECT-FX, CLINICAL TRIAL OF ZYN002 IN FXS.ZYNERBA PHARMACEUTICALS - BELIEVE ADDITIONAL CAPITAL WILL FUND NDA FILING FOR ZYN002 FOR TREATMENT OF BEHAVIORAL SYMPTOMS OF FRAGILE X..
Full Article
July 20 (Reuters) - Zynerba Pharmaceuticals Inc ::ZYNERBA PHARMACEUTICALS ANNOUNCES PRICING OF PUBLIC OFFERING OF COMMON STOCK.SAYS PUBLIC OFFERING OF 4.06 MILLION COMMON SHARES PRICED AT $8.00PER SHARE.
Full Article
July 19 (Reuters) - Zynerba Pharmaceuticals Inc ::ZYNERBA PHARMACEUTICALS ANNOUNCES PROPOSED PUBLIC OFFERING OF COMMON STOCK.ZYNERBA PHARMACEUTICALS - ZYNERBA INTENDS TO USE NET PROCEEDS OF PROPOSED OFFERING TO SUPPORT CLINICAL DEVELOPMENT OF ZYN002, FOR ADDITIONAL RESEARCH AND DEVELOPMENT.
Full Article
July 12 (Reuters) - Zynerba Pharmaceuticals Inc ::ZYNERBA PHARMACEUTICALS ANNOUNCES NEW FAB-C PHASE 2 OPEN-LABEL DATA IN PATIENTS WITH FRAGILE X SYNDROME.ZYNERBA PHARMACEUTICALS - SIGNIFICANT IMPROVEMENTS IN BEHAVIORAL SYMPTOMS OBSERVED IN PATIENTS AND SUSTAINED THROUGH 38 WEEKS OF TREATMENT WITH ZYN002.ZYNERBA PHARMACEUTICALS INC - ZYN002 WAS WELL TOLERATED; NO SERIOUS ADVERSE EVENTS WERE REPORTED.
Full Article
July 5 (Reuters) - Zynerba Pharmaceuticals Inc ::ZYNERBA PHARMACEUTICALS ANNOUNCES TOP LINE RESULTS FROM ZYN001 THC-PRODRUG PATCH PHASE 1 STUDY.ZYNERBA PHARMACEUTICALS INC - ZYN001 WAS VERY WELL TOLERATED WITH MINIMAL SKIN ERYTHEMA.ZYNERBA PHARMACEUTICALS INC - THERE WERE NO SERIOUS ADVERSE EVENTS OR DISCONTINUATIONS FOR SUBJECTS RECEIVING ZYN001.ZYNERBA PHARMACEUTICALS - BELIEVES CASH & CASH EQUIVALENT POSITION AS OF MARCH 31, IS SUFFICIENT TO FUND OPERATIONS & CAPITAL REQUIREMENTS INTO H2 2019.
Full Article
Jan 3 (Reuters) - Zynerba Pharmaceuticals Inc ::ZYNERBA PHARMACEUTICALS PROVIDES 2018 CLINICAL AND CORPORATE UPDATE.ZYNERBA PHARMACEUTICALS INC - PLANS TO INITIATE PHASE 2 DEVELOPMENT OF ZYN001 IN TOURETTE SYNDROME BY YEAR END 2018.ZYNERBA - BELIEVES IT CAN FUND OPERATIONS AND CAPITAL REQUIREMENTS WELL INTO 2019.ZYNERBA PHARMACEUTICALS - WILL CONCENTRATE ITS FOCUS ON RARE AND NEAR-RARE NEUROLOGICAL AND PSYCHIATRIC DISORDERS WITH HIGH UNMET MEDICAL NEEDS.ZYNERBA - IN 2018, CO INTENDS TO DEVELOP ZYN002 IN PIVOTAL PHASE 2/3 PROGRAM IN FRAGILE X SYNDROME AND IN PHASE 2 PROGRAMS IN REFRACTORY EPILEPSIES.ZYNERBA PHARMACEUTICALS INC - PLAN TO INITIATE A PIVOTAL STUDY FOR ZYN002 IN FXS THAT SHOULD READ OUT IN 2019.
Full Article
Nov 14 (Reuters) - Zynerba Pharmaceuticals Inc :Zynerba Pharmaceuticals reports third quarter 2017 financial results and operational highlights.Q3 loss per share $0.63.Q3 earnings per share view $-0.59 -- Thomson Reuters I/B/E/S.Zynerba Pharmaceuticals - believes cash and cash equivalent position as of September 30, 2017 is sufficient to develop five phase 3-ready programs.Zynerba Pharmaceuticals Inc - believes that cash and cash equivalent position of as of September 30, 2017 is sufficient to fund operations into 2019.
Full Article
Earnings vs. 
Estimates